US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
Search
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
About our Innovation Prize
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.
Annual Declaration of Boehringer Ingelheim Corporation’s compliance with its Comprehensive Compliance Program.
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®
Deciphering Circuits in Neuroscience | Boehringer Ingelheim US
Hear from Craig Lindsley, Director of the Warren Center for Neuroscience Drug Discovery on our dedication to improving mental health.
Boehringer Ingelheim Office Hours
Boehringer Ingelheim Office Hours
Full results from EMPERIAL exercise ability trials presented
Full results from EMPERIAL exercise ability trials presented
Results for Jardiance® (empaglifozin) | BI US
Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.
Rising Star Leads with Determination | Boehringer Ingelheim US
Click to find out more on our partnership with the HBA, where we honor a BI colleague as a “Rising Star” to support the advancement of women in health care.
Fighting Non-Communicable Diseases | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
Sunshine Act Compliance
Sunshine Act Compliance
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Boehringer Ingelheim Subsidiaries and Affiliate Companies
Boehringer Ingelheim Subsidiaries and Affiliate Companies
Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US
Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.
Phase III EMPA-KIDNEY trial will stop early
The EMPA-KIDNEY trial, evaluating the effect of Jardiance (empagliflozin) tablets in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee.
Work Care Consortium | COVID-19 | Boehringer Ingelheim US
Click here to read more on Boehringer Ingelheim's work with the CARE Consortium in dealing with the COVID-19 pandemic.
Shanghai
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction
Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction